Home Earnings Preview Sneak Preview of IsoRay, Inc. ($ISR) 4Q20 Earnings

Sneak Preview of IsoRay, Inc. ($ISR) 4Q20 Earnings


IsoRay, Inc. (AMEX:ISR) is expected to report fourth quarter earnings results, after market close, on Thursday 17th September 2020.

Analysts polled by Thomson Reuters anticipate fourth quarter loss of $ 0.01 per share.

Looking ahead, the full year loss are expected at $ 0.04 per share on the revenues of $ 10.10 million.

Previous Quarter Performance

IsoRay, Inc. revealed loss for the third quarter of $ 0.01 per share, from the revenue of $ 2.88 million. The consensus estimates are loss of $ 0.01 per share from $ 2.55 million in revenue. The top line results outshined analysts by $ 0.33 million or 12.94 percent.

Stock Performance

Shares of IsoRay, Inc. traded up $ 0.04 or 5.69 percent on Wednesday, reaching $ 0.71 with volume of 463.90 thousand shares. IsoRay, Inc. has traded high as $ 0.73 and has cracked $ 0.68 on the downward trend

According to the previous trading day, closing price of $ 0.71, representing a 134.48 % increase from the 52 week low of $ 0.29 and a 35.85 % decrease over the 52 week high of $ 1.06.

The company has a market capital of $ 48.27 million and is part of the Healthcare sector and Medical Instruments & Supplies industry.

Conference Call

IsoRay, Inc. will be hosting a conference call at 4:30 PM eastern time on 17th September 2020, to discuss its 4Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.isoray.com

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed.

Previous articleA Sneak Peek At Cantel Medical Corp. ($CMD) 4Q20 Earnings
Next articleStreet Expectation From United Natural Foods, Inc. ($UNFI) 4Q20 Earnings?
Raghav worked in Indian media for about five years. He has done commerce post graduation. He is anxious on covering the Asian markets and wants to be one of the leading journalists in this region. He can be contacted at raghav@stockmarketintellects.com